Icon

TYZEKA (nda022011)- (600MG)

TELBIVUDINE NOVARTIS
600MG
No No
2023-Sep-11 2011-Oct-25
None None
None No
TYZEKA is an HBV nucleoside analogue reverse transcriptase inhibitor indicated for the treatment of chronic hepatitis B in adult patients with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases [alanine aminotransferase (ALT) or aspartate aminotransferase (AST)] or histologically active disease.
0 0 0
Total Other Developers None
Drugs with Suitability No
600MG ** ** - - -
NDA Sales Available Total Generic Sales Available
No 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.